Regencell Bioscience Holdings Ltd (RGC) shareholders
Close on Nov 17, 2026Market cap $2.26BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Yat-Gai Au Joint filing with Regencell (BVI) Limited (86.20%) | 437,896,116 | 88.60% | 13D (active) amendment | Jul 11, 2025 |
| Regencell (BVI) Limited Joint filing with Yat-Gai Au (86.20%) | 11,221,821 | 86.20% | 13D (active) amendment | Mar 10, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RGC | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 422,011 | 0.09% | $2.57M | +6,442 | 0.00% |
| Alyeska Investment Group, L.P. | 416,261 | 0.08% | $2.54M | New | 0.01% |
| Legal & General Group Plc | 128,000 | 0.03% | $778.97K | +118,097 | 0.00% |
| Jane Street Group, LLC | 98,348 | 0.02% | $598.94K | New | 0.00% |
| XTX Topco Ltd | 60,061 | 0.01% | $365.77K | New | 0.00% |
| Amundi | 47,159 | 0.01% | $287.20K | +38,564 | 0.00% |
| UBS Group AG | 43,208 | 0.01% | $263.14K | +19,323 | 0.00% |
| Quadrature Capital Ltd | 41,750 | 0.01% | $254.26K | New | 0.00% |
| Susquehanna International Group, Llp | 23,129 | 0.00% | $140.86K | New | 0.00% |
| Squarepoint Ops LLC | 22,036 | 0.00% | $134.20K | −4,577 | 0.00% |
| Fox Run Management, L.L.C. | 20,691 | 0.00% | $126.01K | New | 0.02% |
| CIBC Asset Management Inc | 15,292 | 0.00% | $93.13K | New | 0.00% |
| Bank Of America Corp /De/ | 14,994 | 0.00% | $91.31K | −2,178 | 0.00% |
| Two Sigma Investments, LP | 14,406 | 0.00% | $87.73K | New | 0.00% |
| Vident Advisory, LLC | 11,199 | 0.00% | $68.20K | −18,389 | 0.00% |
| Morgan Stanley | 5,052 | 0.00% | $30.77K | −15,026 | 0.00% |
| BlackRock, Inc. | 4,925 | 0.00% | $29.99K | −32 | 0.00% |
| State of Wyoming | 4,070 | 0.00% | $24.79K | New | 0.00% |
| Federation des caisses Desjardins du Quebec | 2,803 | 0.00% | $17.07K | +572 | 0.00% |
| Aquatic Capital Management LLC | 2,058 | 0.00% | $12.53K | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 35 | 1M | 0.3% | 16 / 10 | 6 / 12 | 1M | 0M |
| Q1 2026 | 31 | 1M | 0.1% | 18 / 6 | 4 / 4 | 0M | 0M |
| Q4 2025 | 17 | 1M | 0.1% | 7 / 4 | 4 / 6 | 0M | 0M |
| Q3 2025 | 16 | 1M | 0.1% | 7 / 4 | 5 / 5 | 0M | 0M |
| Q2 2025 | 14 | 1M | 0.1% | 11 / 2 | 1 / 2 | 0M | 0M |
| Q1 2025 | 5 | 0M | 0.1% | 3 / 1 | 1 / 1 | 0M | 1M |
| Q4 2024 | 3 | 1M | 0.2% | 1 / 1 | 0 / 0 | 1M | 0M |
| Q3 2024 | 2 | 1M | 0.1% | 1 / 1 | 0 / 1 | 1M | 0M |
| Q2 2024 | 3 | 0M | 0.0% | 0 / 0 | 1 / 0 | 0M | 0M |
| Q1 2024 | 3 | 0M | 0.0% | 0 / 0 | 1 / 0 | 0M | 1M |
| Q4 2023 | 3 | 1M | 0.1% | 1 / 0 | 0 / 2 | 1M | 0M |
| Q3 2023 | 4 | 0M | 0.0% | 2 / 1 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Yat-Gai Au | Chief Executive Officer, Director, 10% owner | 437,896,116 | 88.31% | Mar 18, 2026 |
| James Wai Hong Chung | COO and Chief Strategy Officer, Director | – | – | Mar 18, 2026 |
| Ho Yau Chan | Financial Controller | – | – | Mar 18, 2026 |
| Yat-Pui Au | Chief Business Officer | 581,514 | 0.12% | Mar 18, 2026 |
| William Wing Yan Dr Lo | Director | 485,629 | 0.10% | Nov 17, 2026 |
| Evana Yee Wah Hui | Director | – | – | May 29, 2026 |
| Margaret Hoor Han Lo | Director | 604,050 | 0.12% | Mar 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| William Wing Yan Dr Lo Director | Nov 17, 2026 | Option exercise | +36,001 | $0.84 | $30.24K | 485,629 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Regencell Bioscience's stock actually held short. Settlement fails (shares not delivered on time) peaked at 35,922 shares on Sep 10, 2026 over the last 90 days.
Congress trades
3 trades in Regencell Bioscience reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Lois Frankel FL22 | Sold | Jan 9, 2018 | $1K–15K | Jan 23, 2018 |
| Lois Frankel FL22 | Sold | Jan 8, 2018 | $1K–15K | Jan 23, 2018 |
| Lois Frankel FL22 | Sold | Dec 8, 2017 | $1K–15K | Dec 20, 2017 |
See a number that looks wrong?